NEW YORK, Sept. 23, 2019 (GLOBE NEWSWIRE) -- Levi & Korsinsky, LLP announces that class action lawsuits have commenced on behalf of shareholders of the following publicly-traded companies. Shareholders interested in serving as lead plaintiff have until the deadlines listed to petition the court and further details about the cases can be found at the links provided. There is no cost or obligation to you.
Curaleaf Holdings, Inc. (OTCMKTS: CURLF)
Class Period: November 21, 2018 - July 22, 2019
Lead Plaintiff Deadline: October 4, 2019
Join the action: https://www.zlk.com/pslra-1/curaleaf-holdings-inc-loss-form?wire=3
About the lawsuit: During the class period, Curaleaf Holdings, Inc. allegedly made materially false and/or misleading statements and/or failed to disclose that: (1) Curaleaf, on its website and social media pages, marketed its CBD products to be used as drugs and dietary supplements, contrary to law; (2) Curaleaf also sold unapproved animal drugs on its website; (3) such conduct would result in a warning letter from the U.S. Food and Drug Administration; and (4) as a result, Defendants’ statements about its business, operations, and prospects, were materially false and misleading and/or lacked a reasonable basis at all relevant times.
To learn more about the Curaleaf Holdings, Inc. class action contact jlevi@levikorsinsky.com.
Sarepta Therapeutics, Inc. (NASDAQ: SRPT)
Class Period: September 6, 2017 - August 19, 2019
Lead Plaintiff Deadline: October 29, 2019
Join the action: https://www.zlk.com/pslra-1/sarepta-therapeutics-inc-loss-form?wire=3
About the lawsuit: Sarepta Therapeutics, Inc. allegedly made materially false and/or misleading statements during the class period and/or failed to disclose that: (i) golodirsen, Sarepta's drug for the treatment of Duchenne muscular dystrophy, posed significant safety risks to patients; (ii) consequently, the New Drug Application package for golodirsen’s accelerated approval was unlikely to receive Food and Drug Administration approval; and (iii) as a result, Sarepta’s public statements were materially false and misleading at all relevant times.
To learn more about the Sarepta Therapeutics, Inc. class action contact jlevi@levikorsinsky.com.
Farfetch Limited (NYSE: FTCH)
Class Period: all persons and entities who purchased or otherwise acquired Farfetch Class A ordinary shares between September 21, 2018, and August 8, 2019, inclusive, including those who purchased or otherwise acquired Farfetch Class A ordinary shares pursuant and/or traceable to the registration statement and prospectus issued in connection with Company's September 21, 2018 initial public offering.
Lead Plaintiff Deadline: November 18, 2019
Join the action: https://www.zlk.com/pslra-1/farfetch-loss-form?wire=3
About the lawsuit: During the class period, Farfetch Limited allegedly made materially false and/or misleading statements and/or failed to disclose that: (1) the Company would refuse to reduce merchandise prices to match the rest of the market; (2) this sub-optimal pricing strategy rendered the Company's platform highly susceptible to underpricing by competitors, despite what Defendants touted as a "superior" platform; and (3) as a result, the Company's past and projected Platform Gross Merchandise Value growth rates were foreseeably unsustainable. As a result of the foregoing, Defendants' statements about the Company's business strategy and growth prospects lacked a reasonable basis at all relevant times.
To learn more about the Farfetch Limited class action contact jlevi@levikorsinsky.com.
You have until the lead plaintiff deadlines to request the court appoint you as lead plaintiff. Your ability to share in any recovery doesn’t require that you serve as a lead plaintiff.
Levi & Korsinsky is a national firm with offices in New York, California, Connecticut, and Washington D.C. The firm’s attorneys have extensive expertise and experience representing investors in securities litigation and have recovered hundreds of millions of dollars for aggrieved shareholders. Attorney advertising. Prior results do not guarantee similar outcomes.
CONTACT:
Levi & Korsinsky, LLP
Joseph E. Levi, Esq.
55 Broadway, 10th Floor
New York, NY 10006
jlevi@levikorsinsky.com
Tel: (212) 363-7500
Fax: (212) 363-7171
www.zlk.com
